Fig. 6: Anti-DKK1 lead antibodies cause inhibition of tumor growth.

A The homozygous SCID mice were inoculated with PC3 cells. Dosing was initiated at a tumor volume average of ~100 mm³ with 10 mg/kg antibody via intraperitoneal injection once every 3 days for 8 cycles (Q3D x 8). Tumor sizes were measured 3 times a week (n = 6). B The frequency of CD161⁺ cells within the CD45⁺ cell population was measured on Day 7 post-administration. The number of NK cells increases upon TB725-003 treatment. C Tumor size measurement indicates TB725-003 treatment significantly suppresses tumor growth, demonstrating their efficacy in tumor suppression. No significant difference is observed with mice body weight changes. D Tumor growth inhibition shows 42.89% reduction in size upon TB725-003 treatment, respectively, while the positive control antibody gave 18.88% inhibition. Tumor Growth Inhibition (TGI, %) = [1−(T t − T 0)/(C t − C 0)] × 100%, where T t = mean TV of treated at time t, T 0 = mean TV of treated at time 0 (baseline), Ct = mean TV of control at time t and C 0 = mean TV of control at time 0 (baseline). E No significant changes are observed for mice body weight measurements. **p ≤ 0.01, ***p ≤ 0.001 vs. isotype control by Kruskal–Walli’s test. The study was repeated in triplicate.